Dianthus Therapeutics Hits Early 'Go' in CAPTIVATE Phase 3 CIDP Trial
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 15 2026
0mins
Should l Buy DNTH?
Source: Yahoo Finance
- Trial Design Changes: Dianthus announced that the interim analysis of the CAPTIVATE Phase 3 trial met its responder goal with 20 confirmed NCAT responders, raising the responder assumption to 50%, and eliminating the 600 mg arm, transitioning to a randomized withdrawal study comparing 300 mg to placebo, reducing the projected patient count from 192 to 128, optimizing resource allocation.
- Reassuring Safety Signals: The interim analysis reported no safety events or indications of autoimmune activation, ensuring the safety profile of claseprubart in CIDP patients, which management expressed satisfaction with, believing it will enhance market confidence and drive further research.
- Strong Financial Position: Dianthus management reiterated a cash balance of approximately $514 million as of December 31, 2023, expected to fund operations into 2028, demonstrating the company's financial capability to advance clinical trials and market expansion.
- Significant Market Opportunity: CIDP is viewed as a multi-billion dollar market, with management planning to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, expecting top-line results in the second half of 2028, reflecting the company's confidence in future growth.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy DNTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on DNTH
Wall Street analysts forecast DNTH stock price to fall
6 Analyst Rating
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 81.130
Low
46.00
Averages
77.00
High
125.00
Current: 81.130
Low
46.00
Averages
77.00
High
125.00
About DNTH
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company engaged in designing and delivering monoclonal antibodies with improved selectivity and potency. The Company is focused on developing complement therapeutics for patients living with severe autoimmune and inflammatory diseases. Its advanced product candidate, DNTH103, is a clinical-stage, highly potent, selective and fully human monoclonal immunoglobulin G4 with picomolar binding affinity that is designed to selectively bind only to the active form of C1s. DNTH103 is engineered with YTE half-life extension technology, a specific three amino acid change in the Fc domain, and has a pharmacokinetic (PK) profile designed to support less frequent, lower dose, self-administration as a convenient S.C. injection. It is conducting three mid- to late-stage clinical trials with DNTH103 in generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Dianthus Therapeutics FDA Approves Clinical Changes for Claseprubart
- FDA Approval of Clinical Changes: Dianthus Therapeutics announced that the FDA agreed to several proposed changes for its lead candidate, claseprubart, marking a significant advancement in the treatment of autoimmune diseases, particularly generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
- Impact on Clinical Studies: The FDA's feedback includes changes to screening criteria, routine lab work, and autoimmune safety risk, which will apply to all current and future studies, expected to enhance patient recruitment efficiency and optimize study outcomes.
- Positive Safety Data: Dianthus reported no incidences of systemic lupus erythematosus or drug-induced lupus in any of the claseprubart programs to date, which will bolster confidence among investors and regulators regarding the drug's safety profile.
- Positive Market Reaction: Following the FDA's announcement, Dianthus's shares spiked on Thursday, reflecting market optimism about the company's future clinical developments and further solidifying its position in the biotechnology sector.
See More
5AM Venture Management Fully Exits Dianthus Therapeutics
- Full Exit: On February 17, 2026, 5AM Venture Management disclosed through an SEC filing that it sold its entire stake of 365,053 shares in Dianthus Therapeutics for $14.36 million, indicating a complete exit that may affect market confidence in the company.
- Stock Performance: As of Wednesday, shares of Dianthus Therapeutics were priced at $80.68, reflecting a 288% increase over the past year; however, this exit occurred before much of the stock's recent surge, highlighting the need for investors to focus on the company's future execution.
- Market Capitalization: Dianthus has a market capitalization of $3.5 billion, yet its trailing twelve-month revenue stands at only $3.08 million with a net loss of $126.34 million, indicating that the company remains in a clinical phase with uncertain future profitability.
- R&D Strategy: Dianthus focuses on developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases, with its lead program DNTH103 in clinical trials; despite high risks, its innovative R&D strategy could provide long-term growth potential for the company.
See More
Dianthus Therapeutics Hits Early 'Go' in CAPTIVATE Phase 3 CIDP Trial
- Trial Design Changes: Dianthus announced that the interim analysis of the CAPTIVATE Phase 3 trial met its responder goal with 20 confirmed NCAT responders, raising the responder assumption to 50%, and eliminating the 600 mg arm, transitioning to a randomized withdrawal study comparing 300 mg to placebo, reducing the projected patient count from 192 to 128, optimizing resource allocation.
- Reassuring Safety Signals: The interim analysis reported no safety events or indications of autoimmune activation, ensuring the safety profile of claseprubart in CIDP patients, which management expressed satisfaction with, believing it will enhance market confidence and drive further research.
- Strong Financial Position: Dianthus management reiterated a cash balance of approximately $514 million as of December 31, 2023, expected to fund operations into 2028, demonstrating the company's financial capability to advance clinical trials and market expansion.
- Significant Market Opportunity: CIDP is viewed as a multi-billion dollar market, with management planning to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, expecting top-line results in the second half of 2028, reflecting the company's confidence in future growth.
See More
Dianthus Therapeutics (DNTH.US) Director Plans to Sell $10.55 Million in Common Stock via Form 144
- Stock Sale Announcement: Director Marino Garcia intends to sell 122,920 shares of its common stock on March 12.
- Market Value: The total market value of the shares being sold is approximately $10.55 million.
See More
Dianthus Therapeutics Prices $625 Million Upsized Public Offering
- Upsized Financing: Dianthus Therapeutics is offering 7.31 million shares at $81 each, raising $625 million, expected to close on March 12, 2026, to support multiple programs targeting severe autoimmune and neuromuscular diseases.
- Clinical Trial Advancements: The lead program, Claseprubart, is set to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, with topline results anticipated in 2H 2028, highlighting the company's strategic focus on high unmet medical needs.
- Early Clinical Success: Claseprubart achieved an early
See More
Dianthus Therapeutics Prices Upsized $625 Million Public Offering
- Upsized Offering: Dianthus Therapeutics announced the upsizing of its public offering from an initially proposed $400 million to $625 million, issuing 7.31 million shares at $81.00 each, reflecting strong market demand for its stock.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 402,468 shares priced at $80.999 each, with a low exercise price designed to attract more investors, thereby enhancing its fundraising capabilities.
- Clear Use of Proceeds: The expected total proceeds of approximately $625 million will be utilized for advancing clinical and preclinical development, preparing for commercial readiness, and general corporate purposes, indicating a well-defined strategic plan for future growth.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 1.16 million shares, which adds flexibility and potential scale to the offering, demonstrating market confidence in the company's future growth prospects.
See More
Dianthus Therapeutics FDA Approves Clinical Changes for Claseprubart
- FDA Approval of Clinical Changes: Dianthus Therapeutics announced that the FDA agreed to several proposed changes for its lead candidate, claseprubart, marking a significant advancement in the treatment of autoimmune diseases, particularly generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
- Impact on Clinical Studies: The FDA's feedback includes changes to screening criteria, routine lab work, and autoimmune safety risk, which will apply to all current and future studies, expected to enhance patient recruitment efficiency and optimize study outcomes.
- Positive Safety Data: Dianthus reported no incidences of systemic lupus erythematosus or drug-induced lupus in any of the claseprubart programs to date, which will bolster confidence among investors and regulators regarding the drug's safety profile.
- Positive Market Reaction: Following the FDA's announcement, Dianthus's shares spiked on Thursday, reflecting market optimism about the company's future clinical developments and further solidifying its position in the biotechnology sector.
See More
5AM Venture Management Fully Exits Dianthus Therapeutics
- Full Exit: On February 17, 2026, 5AM Venture Management disclosed through an SEC filing that it sold its entire stake of 365,053 shares in Dianthus Therapeutics for $14.36 million, indicating a complete exit that may affect market confidence in the company.
- Stock Performance: As of Wednesday, shares of Dianthus Therapeutics were priced at $80.68, reflecting a 288% increase over the past year; however, this exit occurred before much of the stock's recent surge, highlighting the need for investors to focus on the company's future execution.
- Market Capitalization: Dianthus has a market capitalization of $3.5 billion, yet its trailing twelve-month revenue stands at only $3.08 million with a net loss of $126.34 million, indicating that the company remains in a clinical phase with uncertain future profitability.
- R&D Strategy: Dianthus focuses on developing monoclonal antibody therapies for severe autoimmune and inflammatory diseases, with its lead program DNTH103 in clinical trials; despite high risks, its innovative R&D strategy could provide long-term growth potential for the company.
See More
Dianthus Therapeutics Hits Early 'Go' in CAPTIVATE Phase 3 CIDP Trial
- Trial Design Changes: Dianthus announced that the interim analysis of the CAPTIVATE Phase 3 trial met its responder goal with 20 confirmed NCAT responders, raising the responder assumption to 50%, and eliminating the 600 mg arm, transitioning to a randomized withdrawal study comparing 300 mg to placebo, reducing the projected patient count from 192 to 128, optimizing resource allocation.
- Reassuring Safety Signals: The interim analysis reported no safety events or indications of autoimmune activation, ensuring the safety profile of claseprubart in CIDP patients, which management expressed satisfaction with, believing it will enhance market confidence and drive further research.
- Strong Financial Position: Dianthus management reiterated a cash balance of approximately $514 million as of December 31, 2023, expected to fund operations into 2028, demonstrating the company's financial capability to advance clinical trials and market expansion.
- Significant Market Opportunity: CIDP is viewed as a multi-billion dollar market, with management planning to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, expecting top-line results in the second half of 2028, reflecting the company's confidence in future growth.
See More
Dianthus Therapeutics (DNTH.US) Director Plans to Sell $10.55 Million in Common Stock via Form 144
- Stock Sale Announcement: Director Marino Garcia intends to sell 122,920 shares of its common stock on March 12.
- Market Value: The total market value of the shares being sold is approximately $10.55 million.
See More
Dianthus Therapeutics Prices $625 Million Upsized Public Offering
- Upsized Financing: Dianthus Therapeutics is offering 7.31 million shares at $81 each, raising $625 million, expected to close on March 12, 2026, to support multiple programs targeting severe autoimmune and neuromuscular diseases.
- Clinical Trial Advancements: The lead program, Claseprubart, is set to initiate a Phase 3 trial for generalized myasthenia gravis in mid-2026, with topline results anticipated in 2H 2028, highlighting the company's strategic focus on high unmet medical needs.
- Early Clinical Success: Claseprubart achieved an early
See More
Dianthus Therapeutics Prices Upsized $625 Million Public Offering
- Upsized Offering: Dianthus Therapeutics announced the upsizing of its public offering from an initially proposed $400 million to $625 million, issuing 7.31 million shares at $81.00 each, reflecting strong market demand for its stock.
- Pre-Funded Warrants: The company is also offering pre-funded warrants for 402,468 shares priced at $80.999 each, with a low exercise price designed to attract more investors, thereby enhancing its fundraising capabilities.
- Clear Use of Proceeds: The expected total proceeds of approximately $625 million will be utilized for advancing clinical and preclinical development, preparing for commercial readiness, and general corporate purposes, indicating a well-defined strategic plan for future growth.
- Underwriters' Option: The underwriters have a 30-day option to purchase an additional 1.16 million shares, which adds flexibility and potential scale to the offering, demonstrating market confidence in the company's future growth prospects.
See More
